Fig. 2From: Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults Assessment of Olipudase Alfa on Liver Volumes A. Individual patient liver volumes by years of olipudase alfa treatment. Liver volumes were calculated by integrating cross-sectional magnetic resonance images and expressed as multiples of normal (MN) where normal liver volume was assumed to be 2.5% of body weight [18]. Severe and moderate hepatomegaly were defined as > 2.5 and > 1.25 to ≤ 2.5MN [18], respectively. Cutoffs of MN for severity of hepatomegaly are indicated by horizontal linesB. Least square (LS) mean percent changes ± SE of the mean in liver volume from baseline over time. All p values are nominalBack to article page